Paula M. Fracasso, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Washington University School Of Medicine - St. Louis MO
Rank: Associate Professor
Years: 1991-2007

University Of Virginia School Of Medicine - Charlottesville VA
Rank: Full Professor
Years: 2007-2014

University Of Virginia School Of Medicine - Charlottesville VA
Rank: Visiting Professor of Medicine
Years: 2014-present

Virginia Commonwealth University School Of Medicine (Previously MCV) - Richmond VA
Rank: Full Professor
Years: 2022-present

None Reported

A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
Cancer Chemother Pharmacol
Volume: 83
Date: 05 2019
pubmed.ncbi.nlm.nih.gov/30535536/

An integrated approach to optimal administration of OX40 agonist antibodies in patients with advanced solid tumors
Clin Cancer Res
Volume: 25
Date: 11 2019
pubmed.ncbi.nlm.nih.gov/31623857/

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patient with recurrent endometrial cancer: An NRG oncology study
Gyn Onc
Volume: 155
Date: 12 2019
pubmed.ncbi.nlm.nih.gov/31623857/

A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Gyn Onc
Volume: 156
Date: 01 2020
pubmed.ncbi.nlm.nih.gov/31708167/

Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer.
AMA Oncology 6:92-99. PMID: 31774464, PMCID: PMC6902184
Volume: 6:92-99
Date: 01 2020
JAMA Oncol . 2020 Jan 1;6(1):92-99. doi: 10.1001/jamaoncol.2019.3857

Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group
Gyn Oncol
158:562-569.
Date: 09 2020
Gynecol Oncol . 2020 Sep;158(3):562-569. doi: 10.1016/j.ygyno.2020.06.493.

Post hoc analyses of GOGO 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gyn Oncol
161:512-515.
Date: 05 2021
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084973/

Phase I study of docetaxel and temsirolimus in refractory solid tumors. PMID 34310349
Am J Clin Oncol
44:443-448.
Date: 09 2021
https://pubmed.ncbi.nlm.nih.gov/34310349/

Phase 1 clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer
J Immunother Cancer
Volume: 10
Date: 01 2022
https://jitc.bmj.com/content/10/1/e003581.info

Phase I clinical trial evaluating the safety and anti-tumor activity of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors.
Front Oncol
Date: 03 2022
https://doi.org/10.3389/fonc.2022.818679.